These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 22002453)

  • 21. A research agenda for economic evaluation of substance abuse services.
    French MT; Drummond M
    J Subst Abuse Treat; 2005 Sep; 29(2):125-37. PubMed ID: 16135341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Substance abuse and family illness: evidence from health care utilization and cost-offset research.
    Lennox RD; Scott-Lennox JA; Holder HD
    J Ment Health Adm; 1992; 19(1):83-95. PubMed ID: 10171039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rx for health care costs: resolving addictions in the general medical setting.
    Langenbucher J
    Alcohol Clin Exp Res; 1994 Oct; 18(5):1033-6. PubMed ID: 7847584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multisite cost analysis of a school-based voluntary alcohol and drug prevention program.
    Kilmer B; Burgdorf JR; D'Amico EJ; Miles J; Tucker J
    J Stud Alcohol Drugs; 2011 Sep; 72(5):823-32. PubMed ID: 21906509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. California drug courts: outcomes, costs and promising practices: an overview of Phase II in a statewide study.
    Carey SM; Finigan M; Crumpton D; Waller M
    J Psychoactive Drugs; 2006 Nov; Suppl 3():345-56. PubMed ID: 17357526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guidelines and challenges for estimating the economic costs and benefits of adolescent substance abuse treatments.
    Zavala SK; French MT; Henderson CE; Alberga L; Rowe C; Liddle HA
    J Subst Abuse Treat; 2005 Oct; 29(3):191-205. PubMed ID: 16183468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Piloting the development of a cost-effective evidence-informed clinical pathway: managing hypertension in Jordanian primary care.
    Chalkidou K; Lord J; Obeidat NA; Alabbadi IA; Stanley AG; Bader R; Momani A; O'Mahony RM; Qatami L; Cutler D
    Int J Technol Assess Health Care; 2011 Apr; 27(2):151-8. PubMed ID: 21473813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health outcomes and cost-effectiveness of diversion programs for low-level drug offenders: A model-based analysis.
    Bernard CL; Rao IJ; Robison KK; Brandeau ML
    PLoS Med; 2020 Oct; 17(10):e1003239. PubMed ID: 33048929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimating costs of mental health and substance abuse coverage.
    Frank RG; McGuire TG
    Health Aff (Millwood); 1995; 14(3):102-15. PubMed ID: 7498883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimating the costs of substance abuse: implications to the estimation of the costs and benefits of gambling.
    Single E
    J Gambl Stud; 2003; 19(2):215-33. PubMed ID: 12766470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Substance misuse prevention and economic analysis: challenges and opportunities regarding international utility.
    Guyll M; Spoth R; Cornish MA
    Subst Use Misuse; 2012; 47(8-9):877-88. PubMed ID: 22676560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes and costs of matching the intensity of dual-diagnosis treatment to patients' symptom severity.
    Chen S; Barnett PG; Sempel JM; Timko C
    J Subst Abuse Treat; 2006 Jul; 31(1):95-105. PubMed ID: 16814015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost Savings from a Navigator Intervention for Repeat Detoxification Clients.
    Hodgkin D; Brolin MF; Ritter GA; Torres ME; Merrick EL; Horgan CM; Hopwood JC; De Marco N; Gewirtz A
    J Ment Health Policy Econ; 2019 Mar; 22(1):3-13. PubMed ID: 30991351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic Impact of the Statewide Implementation of an Evidence-Based Treatment: Multisystemic Therapy in New Mexico.
    Dopp AR; Coen AS; Smith AB; Reno J; Bernstein DH; Kerns SEU; Altschul D
    Behav Ther; 2018 Jul; 49(4):551-566. PubMed ID: 29937257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient and program costs, and outcomes, of including gender-sensitive services in intensive inpatient programs for substance use.
    Hornack SE; Yates BT
    Eval Program Plann; 2017 Dec; 65():139-147. PubMed ID: 28869868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Where are the economic guidelines coming from?
    McGuire A; Morris S; Raikou M
    Int J Technol Assess Health Care; 2000; 16(4):976-86. PubMed ID: 11155846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cost and cost-effectiveness of an enhanced intervention for people with substance abuse problems at risk for HIV.
    Zarkin GA; Lindrooth RC; Demiralp B; Wechsberg W
    Health Serv Res; 2001 Jun; 36(2):335-55. PubMed ID: 11409816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guidelines for completing the EURONHEED transferability information checklists.
    Nixon J; Rice S; Drummond M; Boulenger S; Ulmann P; de Pouvourville G
    Eur J Health Econ; 2009 May; 10(2):157-65. PubMed ID: 18618158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The problem of replicability in program evaluation. The component solution using the example of case management.
    Graham K; Birchmore-Timney C
    Eval Program Plann; 1989; 12(2):179-87. PubMed ID: 10318227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A critical review of accounting and economic methods for estimating the costs of addiction treatment.
    Cartwright WS
    J Subst Abuse Treat; 2008 Apr; 34(3):302-10. PubMed ID: 17614244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.